Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
FemtoVox General Information
FemtoVox is developing a femtosecond laser surgical platform designed to deliver sub-surface tissue ablation with minimal surface damage, aiming to improve outcomes for delicate surgeries such as those involving the voice box. Early results suggest potential for higher precision and lower complication rates compared to traditional methods. The company has entered a know-how agreement with Mayo Clinic to accelerate development but has not yet reported clinical trial data or commercial launches as of mid 2025.
Contact Information
Primary Industry
Surgical Medical Devices
Corporate Office
Ladera Ranch, California
United States
United States
Drug Pipeline
No pipeline data available
Key Partnerships
Mayo Clinic (know-how agreement/collaboration on technology development)
FemtoVox Funding
No funding data available
To view FemtoVox's complete valuation and funding history, request access »